This reports provides a data-driven overview of the current and future competitive landscape in Frontotemporal Dementia therapeutics.
In 2024, more than 700,000 diagnosed prevalent cases of FTD are anticipated in the 16 countries covered in the analyst’s epidemiology forecast for FTD.
There are currently no approved therapies for FTD in the market.
The FTD pipeline is notably sparse, with no assets in the pre-registration stage, a single asset in Phase III development.
Over the past 10 years, a total of 55 trials have been conducted in FTD. The year with the most trials initiated was 2023, with nine trials.
Partnership dominated the deal landscape in most geographies.
Scope
The Frontotemporal Dementia: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include :
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Frontotemporal Dementia market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Frontotemporal Dementia market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Table of Contents (PowerPoint Deck)
1 Preface
1.1 Contents 1.2 Report Scope 1.3 List of Tables and Figures 1.4 Abbreviations
4.1 Leading Marketed Drugs 4.2 Overview by Mechanism of Action 4.3 Overview by Molecule Type 4.4 Product Profiles and Sales Forecast
5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy 5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs 6.2 Overview by Development Stage 6.3 Overview by Mechanism of Action 6.4 Overview by Molecule Type 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) 6.6 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview 7.2 Overview by Phase 7.3 Overview by Status 7.4 Overview by Phase for Ongoing and Planned Trials 7.5 Trials with Virtual Components 7.6 Overview of Trials by Geography 7.7 Single-Country and Multinational Trials by Region 7.8 Top 20 Sponsors with Breakdown by Phase 7.9 Top 20 Sponsors with Breakdown by Status 7.10 Overview by Endpoint Status 7.11 Overview by Race and Ethnicity 7.12 Enrollment Data 7.13 Top 20 countries for Trial Sites 7.14 Top 20 Sites Globally 7.15 Feasibility Analysis - Geographic Overview 7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
11.1 Methodology 11.2 Methodology - Sales Forecast 11.3 Methodology - Pricing and Reimbursement 11.4 Methodology - PTSR and LoA Analysis 11.5 About the Authors 11.6 Contact the Publisher 11.7 Disclaimer
Within the context of Central Nervous System (CNS) drugs, the Frontotemporal Dementia (FTD) market is focused on therapeutic interventions for managing the symptoms of this group of disorders, which affect the frontal and temporal lobes of the brain. CNS drugs encompass a wide range of medications designed to treat neurological and psychiatric conditions. For FTD, this includes medications that aim to alleviate behavioral disturbances, support cognitive function, and improve quality of life for patients. Since there is currently no cure for FTD, treatment is symptomatic and supportive, often involving off-label use of antipsychotics, antidepressants, and other agents used in various neurological disorders. Research within this market is aimed at understanding the pathophysiology of FTD to develop targeted therapies that can modify the disease's progression or affect its root cause.
Companies active in the FTD market are engaged in the development of drug candidates that can potentially provide a disease-modifying effect or offer more effective symptom management. These include large pharmaceutical firms with diversified CNS portfolios, as well as smaller biotech companies specializing in neurodegenerative disorders. Some of these companies are Alector, Biogen, Lundbeck, and Eli Lilly and Company, which are involved in researching and developing treatments that address the pathological mechanisms underlying Frontotemporal Dementia or improve patient symptoms. Show Less Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF.